Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Market Cap	$2.96B	P/E Ratio	10.50
52W High	$26.58	52W Low	$19.05
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	53.7%	52W Position	79.0%
Overall Score	70	Value Score	80
Quality Score	68	Technical Score	63

EPS Current Est	$2.38	EPS Next Est	$2.39
EPS Growth Est	+0.4%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CPRX	$25.00	+2.88%	1.22M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CPRX	$25.00	+2.9%	1.22M
3
4
5
6

CPRX

CPRX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Catalyst Pharmaceuticals Inc. Data in Excel

Get Catalyst Pharmaceuticals Inc. Data in Excel